tbuckley/cabot-search huggingface dataset:
ASXL1 Mutations Detectable at Diagnosis May Predict Response to Imatinib in Patients with Chronic Myeloid Leukemia
Authors: Marcin M Machnicki, Monika Pepek, Iwona Solarska, Joanna Niesiobedzka-Krezel, Ilona Seferynska, Joanna Gora Tybor, Magdalena Zawada, Tomasz Sacha, Waldemar Sawicki, Ewa Wasilewska, Katarzyna Pruszczyk, Malgorzata Rydzanicz, Rafal Ploski, Tomasz Skorski, Tomasz Stoklosa
Journal: Blood (2019)
Mechanistic Evaluation of Efficacy Using Biomarkers of the Oral, Small Molecule Factor D Inhibitor, Danicopan (ACH-4471), in Untreated Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)
Authors: Antonio M. Risitano, Jong Wook Lee, Rosario Notaro, Robert A. Brodsky, Austin Kulasekararaj, Jaroslaw P. Maciejewski, Mingjun Huang, Michael Geffner, Peter Browett
Journal: Blood (2019)
Comprehensive Analysis of MYC Translocations in Multiple Myeloma By Whole Genome Sequencing and Whole Transcriptome Sequencing
Authors: Sonja Seliger, Verena Geirhos, Torsten Haferlach, Wolfgang Kern, Wencke Walter, Manja Meggendorfer, Constance Baer, Anna Stengel, Claudia Haferlach
Journal: Blood (2019)
PATH-46. DETECTING MISDIAGNOSED ATYPICAL TERATOID/RHABDOID TUMOR (ATRT) BY DNA METHYLATION-BASED TUMOR CLASSIFICATION
Authors: Meng-Chang Hsiao, Lauren Holinka, Michael Peracchio, Kevin Kelly, Andrew Hesse, Ching Lau, Honey Reddi
Journal: Neuro-Oncology (2019)

Abstract Brain tumor diagnostics is achieved by combining morphology assessment and biomarker identification. However, the inter-observer variability of the histopathological diagnosis and lack of distinctive biomarkers makes these diagnoses particularly challenging. Recently, the potential for methylation-based characterization has been developed for brain tumors. To provide accurate and efficient brain tumor diagnostics, The Jackson Laboratory developed a DNA methylation array (Illumina Infinium HD Methylation EPIC), combining the “Classifier” established by the German Cancer Research Center (DKFZ), which can identify 82 distinct central nervous system tumors. Here we present a pediatric patient referred to us for medulloblastoma subtype classification by the methylation profile. Surprisingly, the array classified the tumor type as atypical teratoid/rhabdoid tumor (ATRT), subclass SHH. Also, the CNV profile indicated the SMARCB1/INI1 heterozygous deletion as part of the chromosome 22q deletion typically seen in ATRT, and absent was the isochromosome 17q commonly associated with medulloblastoma. Immunohistochemistry confirmed the loss of SMARCB1/INI1 expression leading to ATRT. Additionally, our NGS panel found a novel SMARCB1/INI1 frameshift variant c.1150delG (p.Ala384fs) in the last exon (exon 9). Although this variant is not expected to induce nonsense-mediated mRNA decay, it is located in the ATP-dependent nucleosome-remodeling complex domain Sfh1/SNF5 (IPR017393), which is associated with cell proliferation and differentiation. In addition, ClinVar reported several pathogenic/likely pathogenic variants in this domain, further supporting SMARCB1/INI1 c.1150delG which, together with the SMARCB1/INI1 deletion, may contribute to the loss of SMARCB1/INI1 expression, resulting in ATRT. We have identified the ATRT misclassification by the methylation profile and characterized a novel SMARCB1/INI1 variant c.1150delG most likely contributing to ATRT. We further propose that the DNA methylation profile will significantly improve the brain tumor diagnostics for cases with ambiguous, or contradictory histology and molecular profiles.
Intermediate Vs High Dose Busulfan-Based Conditioning for Allogeneic Cell Transplantation in Patients with Acute Leukemia or Myelodysplastic Syndromes from HLA Matched Related or Unrelated Donors: Achieving the Same with Less
Authors: Mohamad Sobh, Lothar B. Huebsch, Mitchell Sabloff, Jill Fulcher, Sultan Altouri, Michael Kennah, Elizabeth Drouin, David S. Allan, Harold Atkins, Grace Christou, Pierre Villeneuve, Alexandre P.Blanchard, Kelsey Maclellan, Ranjeeta Mallick, Nicole B. Laferriere, Sathish Gopalakrishnan, Sita D. Bhella, Natasha Kekre, Christopher Bredeson
Journal: Blood (2019)
PD2.02 Pembrolizumab plus Pemetrexed-Platinum for Patients with Metastatic Nonsquamous NSCLC and Liver or Brain Metastases: Results from KEYNOTE-189
Authors: M.C. Garassino, S. Gadgeel, E. Esteban, E. Felip, G. Speranza, F. De Angelis, M. Domine, P. Clingan, M.J. Hochmair, S.F. Powell, S.Y.-S. Cheng, H.G. Bischoff, N. Peled, F. Grossi, R.R. Jennens, M. Reck, R. Hui, E.B. Garon, M. Boyer, B. Rubio-Viqueira, S. Novello, T. Kurata, J.E. Gray, A. Cardellino, J. Yang, M.C. Pietanza, D. Rodríguez-Abreu
Journal: Journal of Thoracic Oncology (2019)
Automatic Bone Marrow Cell Identification and Classification By Deep Neural Network
Authors: Ta-Chuan Yu, Wen-Chien Chou, Chao-Yuan Yeh, Cheng-Kun Yang, Sheng-Chuan Huang, Feng Ming Tien, Chi-Yuan Yao, Chieh-Lung Cheng, Ming-Kai Chuang, Hwei-Fang Tien, Qun-Yi Zhang, Wei-Han Hsu, Sheng-Cheih Chou
Journal: Blood (2019)
Pacritinib Demonstrates Efficacy Versus Best Available Therapy in Myelofibrosis Patients with Severe Thrombocytopenia in Two Phase 3 Studies
Authors: Ruben A. Mesa, Moshe Talpaz, Jean-Jacques Kiladjian, Claire N Harrison, Srdan Verstovsek, Sarah A Buckley, Karisse Roman-Torres, John Mascarenhas
Journal: Blood (2019)
Salt-inducible kinase inhibition suppresses acute myeloid leukemia progression in vivo
Authors: Yusuke Tarumoto, Shan Lin, Jinhua Wang, Joseph P. Milazzo, Yali Xu, Bin Lu, Zhaolin Yang, Yiliang Wei, Sofya Polyanskaya, Mark Wunderlich, Nathanael S. Gray, Kimberly Stegmaier, Christopher R. Vakoc
Journal: Blood (2019)
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study
Authors: Michel Attal, Paul G Richardson, S Vincent Rajkumar, Jesus San-Miguel, Meral Beksac, Ivan Spicka, Xavier Leleu, Fredrik Schjesvold, Philippe Moreau, Meletios A Dimopoulos, Jeffrey Shang-Yi Huang, Jiri Minarik, Michele Cavo, H Miles Prince, Sandrine Macé, Kathryn P Corzo, Frank Campana, Solenn Le-Guennec, Franck Dubin, Kenneth C Anderson, Michel Attal, Paul G. Richardson, Vincent Rajkumar, Jesus San-Miguel, Meral Beksac, Ivan Spicka, Xavier Leleu, Fredrik Schjesvold, Philippe Moreau, Meletios A. Dimopoulos, Jeffrey Shang-Yi Huang, Jiri Minarik, Michele Cavo, H. Miles Prince, Sandrine Macé, Kathryn P. Corzo, Frank Campana, Solenn Le-Guennec, Franck Dubin, Kenneth C. Anderson, Simon Harrison, Wojt Janowski, Ian Kerridge, Andrew Spencer, Michel Delforge, Karel Fostier, Philip Vlummens, Ka Lung Wu, Richard Leblanc, Michel Pavic, Michael Sebag, Roman Hajek, Vladimir Maisnar, Ludek Pour, Henrik Gregersen, Lotfi Benbouker, Denis Caillot, Martine Escoffre-Barbe, Thierry Facon, Laurent Frenzel, Cyrille Hulin, Lionel Karlin, Brigitte Kolb, Brigitte Pegourie, Aurore Perrot, Mourad Tiab, Laure Vincent, Dietger Niederwieser, Achilles Anagnostopoulos, Sosana Delimpasi, Marie-Christine Kyrtsonis, Anargyros Symeonidis, Arpad Illes, Gabor Mikala, Zsolt Nagy, Sara Bringen, Paolo Corradini, Ciceri Fabio, Roberto Lemoli, Anna Liberati, Chiara Nozzoli, Renato Zambello, Shinsuke Iida, Takashi Ikeda, Satoshi Iyama, Morio Matsumoto, Chihiro Shimazaki, Kazutaka Sunami, Kenshi Suzuki, Michihiro Uchiyama, Youngil Koh, Kihyun Kim, Jae Hoon Lee, Chang-Ki Min, Hillary Blacklock, Hugh Goodman, Annette Neylon, David Simpson, Sebastian Grosicki, Artur Jurczyszyn, Adam Walter-Croneck, Krzysztof Warzocha, Luis Araujo, Claudia Moreira, Vadim Doronin, Larisa Mendeleeva, Vladimir Vorobyev, Andrej Vranovsky, Adrian Alegre, Mercedes Gironella, Marta Sonia Gonzalez Perez, Carmen Montes, Enrique Ocio, Paula Rodriguez, Mats Hardling, Birgitta Lauri, Ming-Chung Wang, Su-Peng Yeh, Mutlu Arat, Fatih Demirkan, Zafer Gulbas, Sevgi Kalayoglu Besisik, Ihsan Karadogan, Tulin Tuglular, Ali Unal, Filiz Vural, Jonathan Sive, Matthew Streetly, Kwee Yong, Jason Tache
Journal: The Lancet (2019)
ATIM-24. DOSE FINDING AND DOSE EXPANSION TRIAL OF D2C7 IMMUNOTOXIN (D2C7-IT) ADMINISTERED INTRATUMORALLY VIA CONVECTION-ENHANCED DELIVERY (CED) FOR RECURRENT MALIGNANT GLIOMA (MG)
Authors: Annick Desjardins, Dina Randazzo, Vidya Chandramohan, Katherine Peters, Margaret Johnson, Stevie Threatt, Chevelle Bullock, Jenny Jackman, Patrick Healy, Eric Lipp, John Sampson, Allan Friedman, Henry Friedman, David Ashley, Darell Bigner
Journal: Neuro-Oncology (2019)

Abstract BACKGROUND D2C7-IT is a recombinant immunotoxin comprised of a dual-specific antibody fragment targeting EGFRwt and EGFRvIII and a genetically engineered form of the Pseudomonas exotoxin, PE38-KDEL. We report results of a phase 1 trial, with dose expansion at the selected phase 2 dose, evaluating D2C7-IT delivered intratumorally by CED. METHODS Eligible patients are adults with recurrent supratentorial WHO grade III or IV MG; solitary tumor; ≥4 weeks after chemotherapy, bevacizumab or study drug; adequate organ function; and KPS &gt;70%. Two patients per dose level (DL) were to be enrolled in the dose escalation portion (dose range: 40ng/mL to 23,354ng/mL), followed by dose expansion at the selected phase 2 dose (DL13). RESULTS As of 6/07/2019, 51 patients have been treated; 10 patients on the phase 2 dose. Observed dose limiting toxicities include: grade 4 seizure (n=1) on DL3, grade 3 confusion and pyramidal tract syndrome (n=1) on DL13, and grade 4 cerebral edema (n=1) and grade 3 dysphasia (n=1) on DL17. Grade 3 or higher adverse events possibly related to D2C7-IT include: seizure (grade 4, n=2, grade 3, n=3), cerebral edema (grade 4, n=1), hydrocephalus (grade 3, n=5), headache (grade 3, n=4), hemiparesis (grade 3, n=4), dysphasia (grade 3, n=4), lymphopenia (grade 3, n=3), thromboembolic event (grade 3, n=3); and one each of grade 3 elevated ALT, urinary tract infection, fall, wound complication, generalized muscle weakness, confusion, encephalopathy, and somnolence. Fourteen patients are alive. Three patients have partial radiographic response and remain alive without additional therapy more than 46, 27 and 21 months after D2C7-IT infusion. CONCLUSION Dose level 13 was selected as the optimal phase 2 dose and patient accrual is ongoing on the dose expansion arm. Encouraging efficacy results have been observed. A trial of D2C7-IT with checkpoint inhibitor is planned to start in the near future.
The B-Cell Receptor Antigen ARS2 Can be Integrated into a BAR-Body Format to Treat Diffuse Large B-Cell Lymphomas in Xenograft Mouse Models
Authors: Moritz Bewarder, Christina Körbel, Matthias W. Laschke, Michael D. Menger, Maximilian Kiefer, Dominic Kaddu-Mulindwa, Helene Will, Lisa Goerens, Natalie Fadle, Evi Regitz, Stephan Stilgenbauer, Frank Neumann, Klaus Dieter Preuss, Michael Pfreundschuh, Lorenz Thurner
Journal: Blood (2019)
Maintenance and Consolidation Regimens after a Second Autologous Transplant for Multiple Myeloma: A Decade of Experiences
Authors: Ghulam Rehman Mohyuddin, Maire Okoniewski, Osama Diab, Siddhartha Ganguly, Al-Ola Abdallah, Leyla Shune, Joseph P. McGuirk, Brian McClune
Journal: Blood (2019)
ACTR-35. A STUDY OF RACE AND SOCIOECONOMIC STATUS IMPACTING THERAPEUTIC CLINICAL TRIAL ENROLLMENT IN ADULT GLIOMAS PATIENTS
Authors: Ramin Morshed, Sheantel Reihl, Sofia Kakaizada, Eric Zhang, Jacob Young, Jennifer Clarke, Nicholas Butowski, Jennie Taylor, Nancy Ann Oberheim-Bush, Manish Aghi, Mitchel Berger, Susan Chang, Shawn Hervey-Jumper
Journal: Neuro-Oncology (2019)

Abstract OBJECT Under-enrollment in clinical trials significantly limits valid analyses of clinical interventions and generalizability of findings. Often it results in premature study termination, with estimates of 22% to 50% of clinical trials terminated due to poor accrual. Currently, there are limited reports addressing the influence of race/ethnicity and socioeconomic status on clinical trial enrollment in patients with adult glioma. The goal of this study was to determine if these factors impact clinical trial participation for glioma patients. METHODS 852 adult patients were identified from the UCSF Tumor Board Registry and analyzed to determine the rate of therapeutic clinical trial consideration, tumor board recommendation, and study enrollment based on clinical reports in their electronic medical records. RESULTS At initial diagnosis, 30.7% and 18.0% of glioma patients were recommended and enrolled in a therapeutic clinical trial, respectively. At recurrence, 38.7% and 25.3% of patients were recommended and enrolled in a clinical trial, respectively. Nineteen percent of the study population belonged to a NIH-designated underrepresented minority group; Asian/Pacific-Islander comprising 10.3% overall. On univariate analysis, only in-state location, distance to the hospital, and WHO grade were associated with consideration, recommendation, and enrollment at initial diagnosis and recurrence. Minority status, insurance type, median household income, and percent below poverty were not associated with clinical trial recommendation or enrollment. CONCLUSION Race and socioeconomic status did not impact clinical trial consideration, tumor board recommendation, or study enrollment. Our results do not support the premise that provider decisions are impacted by biases based on minority or socioeconomic status.
Abstract 487: A high percentage of LCNEC shows DLL3 expression in association with molecular subtypes and neuroendocrine markers
Authors: Ernst-Jan M. Speel, Bregtje C. Hermans, Jules L. Derks, Erik Thunnissen, Robert Jan van Suylen, Michael A. den Bakker, Harry J. Groen, Egbert F. Smit, Ronald A. Damhuis, Esther C. van den Broek, Cecile M. Stallinga, Guido M. Roemen, Anne-Marie C. Dingemans
Journal: Cancer Research (2019)

Abstract Background Pulmonary large cell neuroendocrine carcinoma (LCNEC) can be subdivided in two types: the co-mutated TP53 and RB1 subtype, and the TP53 and STK11/KEAP1 mutated subtype (Derks et al. Clin Cancer Res 2018; J Thorac Oncol 2018). DLL3 is a member of the Notch ligand family and a possible treatment target for neuroendocrine carcinoma. We investigated DLL3 and NE marker expression in mutational subtypes of metastatic LCNEC. Methods Immunohistochemical (IHC) analysis for DLL3 (clone SC16.65) was performed on 94 pathological reviewed pretreatment stage IV LCNEC. Samples were scored positive if ≥1% tumor cells showed cytoplasmic or dotlike DLL3 immunostaining. Also an H-score was calculated by multiplying intensity by percentage of positive cells. Targeted next generation sequencing (TP53, RB1, STK11, KEAP1) could be performed in 66 patients. Results DLL3 was expressed in 70/94 (75%) LCNEC, 56 of which showed cytoplasmic immunostaining. 37/70 (53%) samples had an H-score&amp;gt;100. DLL3 staining was more often seen in STK11 and/or KEAP1 mutated LCNEC (13/14;93%) than in tumors with wildtype STK11/KEAP1 (36/52;69%) (trend;p=0.093). In addition, DLL3 positivity was associated with expression of ≥2 NE-markers (64/79 LCNEC (81%) vs 3/8 (37%) tumors with &amp;lt;2 NE-markers; p=0.014). Conclusions A high percentage (75%) of stage IV LCNEC shows cytoplasmatic DLL3 epression in association with NE markers, half of which with H-scores&amp;gt;100. Interestingly, DLL3 positivity was observed in almost all STK11/KEAP1 mutated LCNEC, which is in agreement with recent data (George et al. Nat Commun 2018). It thus might be worthwhile to investigate the efficacy of DLL3 targeted therapy in LCNEC. Citation Format: Ernst-Jan M. Speel, Bregtje C. Hermans, Jules L. Derks, Erik Thunnissen, Robert Jan van Suylen, Michael A. den Bakker, Harry J. Groen, Egbert F. Smit, Ronald A. Damhuis, Esther C. van den Broek, Cecile M. Stallinga, Guido M. Roemen, Anne-Marie C. Dingemans. A high percentage of LCNEC shows DLL3 expression in association with molecular subtypes and neuroendocrine markers [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 487.
A Phase II Trial Evaluating the Efficacy and Safety of Sargramostim Post Infusion of T -Replete HLA Mismatched Peripheral Blood Haploidentical Hematopoietic Stem Cells with Post Transplant Cyclophosphamide
Authors: Melhem Solh, Scott R. Solomon, H. Kent Holland, Lawrence E Morris, Asad Bashey
Journal: Blood (2019)
The Predictors and Prevention of the Central Nervous System Relapse in Patients with Extranodal NK/T Cell Lymphoma, Nasal Type
Authors: Hyera Kim, Eo Jin Kim, Sang Eun Yoon, Youngil Koh, Dok Hyun Yoon, Seok Jin Kim, Sung-Soo Yoon, Hong Ghi Lee, Won Seog Kim
Journal: Blood (2019)
Role of Racial, Demographic and Socioeconomic Disparities in Treatment Patterns and Outcomes in AML
Authors: Ivy Abraham, Garth Rauscher, Anand Ashwin Patel, Wendy Stock, Maryam Zia, Sushma Bharadwaj, Koosha Paydary, Maria Acevedo-Mendez, John P Galvin, William Pearse, Jessica K. Altman, John G. Quigley, Priya Rajakumar, Melissa L. Larson, Irum Khan
Journal: Blood (2019)
HEPATITIS C TRIALS THAT COMBINE INVESTIGATIONAL AGENTS WITH PEGYLATED-INTERFERON-alpha SHOULD BE STRATIFIED BY IL28B GENOTYPE
Authors: Alexander J. Thompson, Andrew J. Muir, Mark S. Sulkowski, Keyur Patel, Hans L. Tillmann, Paul J. Clark, Susanna Naggie, Jacques Fellay, Dongliang Ge, Jeanette McCarthy, David B. Goldstein, John G. McHutchison
Journal: Hepatology (2010)
Impact of Minimal Residual Disease Detected By Multiparameter Flow Cytometry on Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia Patients in First Complete Remission
Authors: Zoya V. Konova, Elena N. Parovichnikova, Irina V. Galtseva, Nikolay M. Kapranov, Julia O. Davydova, Mikhail Yu. Drokov, Maria V. Nareyko, Natalia N. Popova, Anna A. Dmitrova, Ulyana V. Maslikova, Olga S. Starikova, Ekaterina I. Usikova, Ekaterina D. Mikhaltsova, Olga M. Koroleva, Vera A. Vasilyeva, Tatiana I. Lobanova, Larisa A. Kuzmina, Valeriy G. Savchenko
Journal: Blood (2019)
A Comparison of Two LDL Cholesterol Targets after Ischemic Stroke
Authors: Amarenco P, Kim Js, Labreuche J, Charles H, Abtan J, Béjot Y, Cabrejo L, Cha Jk, Ducrocq G, Giroud M, Guidoux C, Hobeanu C, Kim Yj, Lapergue B, Lavallée Pc, Lee Bc, Lee Kb, Leys D, Mahagne Mh, Meseguer E, Nighoghossian N, Pico F, Samson Y, Sibon I, Steg Pg, Sung Sm, Touboul Pj, Touzé E, Varenne O, Vicaut É, Yelles N, Bruckert E
Journal: New England Journal of Medicine (2019)

The use of intensive lipid-lowering therapy by means of statin medications is recommended after transient ischemic attack (TIA) and ischemic stroke of atherosclerotic origin. The target level for low-density lipoprotein (LDL) cholesterol to reduce cardiovascular events after stroke has not been well studied.
Childhood Psychosis or Mental Retardation: A Diagnostic Dilemma. II. Pediatric and Neurological Aspects
Authors: G G HINTON
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Safety and Efficacy of Autologous Stem Cell Transplantation in Dialysis-Dependent Myeloma Patients - the Diadem Study from the Chronic Malignancies Working Party of the EBMT
Authors: Anna Waszczuk-Gajda, Junfeng Wang, Liesbeth C. de Wreede, Tiarlan Sirait, Zubeyde Nur Ozkurt, John A Snowden, Peter Dreger, Árpád Illés, Mutlu Arat, Claude-Eric Bulabois, Herrad Baurmann, Matjaz Sever, Grzegorz W Basak, Manos Nikolousis, Victoria Potter, Wilfried Schroyens, Emmanuel Gyan, Gwendolyn Van Gorkom, Javier de la Serna, Blandine Guffroy, Patrick J Hayden, Meral Beksac, Stefan O. Schönland, Ibrahim Yakoub-Agha
Journal: Blood (2019)
Fitness and Anthracycline Use in Front-Line Therapy for Older Patients with Classical Hodgkin Lymphoma: A US Multi-Center Retrospective Analysis
Authors: Victor M. Orellana-Noia, Krista Isaac, Nolan A Wages, Mary-Kate Malecek, Nancy L. Bartlett, Timothy J Voorhees, Natalie S Grover, Steven R. Hwang, N. Nora Bennani, Rachel Hu, Brian T. Hill, Eric Mou, Ranjana H Advani, Jordan Carter, Kevin A. David, Hatcher J. Ballard, Jakub Svoboda, Gabriela Magarelli, Tatyana A. Feldman, Michael C. Churnetski, Jonathon B. Cohen, Andrew M. Evens, Craig A. Portell
Journal: Blood (2019)
Cost-Effectiveness Analysis of Gilteritinib Versus Best Supportive Care (BSC) for the Treatment of Relapsed or Refractory (R/R) FLT3 Mutation-Positive (FLT3mut+) Acute Myeloid Leukemia (AML)
Authors: Amer M. Zeidan, Bhavik J. Pandya, Cynthia Z. Qi, Andy Garnham, Hongbo Yang, Manasee V Shah
Journal: Blood (2019)
The prognostic value of tumor mitotic rate in children and adolescents with cutaneous melanoma: A retrospective cohort study
Authors: Norbertus A. Ipenburg, Serigne N. Lo, Ricardo E. Vilain, Lodewijka H.J. Holtkamp, James S. Wilmott, Omgo E. Nieweg, John F. Thompson, Richard A. Scolyer
Journal: Journal of the American Academy of Dermatology (2019)
Use of High-Throughput Sequencing (HTS) of TCRß to Determine the Kinetics of Graft-Versus-Lymphoma (GVL) Effect and T-Cell Repertoire Profiles after Allogeneic Transplant
Authors: Wen-Kai Weng, Randall Armstrong, Sally Arai, Richard T. Hoppe, Everett H. Meyer, Youn H. Kim
Journal: Blood (2014)
THE DOCTOR'S CREED
Authors: H. Crichton-Miller, T. Cecil Gray, A.P. Cawadias, J.W. Linnell, H.E. Collier, S.R. Sims, G.K. Mckee, P.R. Boucher, George Johnson, G.L. Davies, HarryF. West
Journal: The Lancet (1949)